Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

4.0K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.0K
Tumor Progression02:07

Tumor Progression

6.1K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.1K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

3.6K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.6K
Destabilization of Microtubules01:45

Destabilization of Microtubules

2.8K
The destabilization of microtubules can occur during different stages of the microtubule lifecycle, such as nucleation or elongation. It can take place at either end of the microtubule or in the microtubule lattices as a whole. The lifespan of individual microtubules within a cell varies according to the cell type and stage of the cell cycle. During interphase, the lifespan of the microtubule is about 30 minutes, while during cell division, it is about 15 minutes. In axonal microtubules of...
2.8K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

6.3K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Use of liposomal irinotecan with 5-FU and oxaliplatin (NALIRIFOX) in neoadjuvant pancreatic adenocarcinoma: NEO-Nal-IRI trial.

The oncologist·2026
Same author

Effect of Treatment Delay on Outcomes With Adjuvant Chemotherapy Versus Chemoradiotherapy in R1-Resected Biliary Tract Cancers.

American journal of clinical oncology·2026
Same author

Using cell-free DNA tumor methylation score to detect and monitor cholangiocarcinoma.

HPB : the official journal of the International Hepato Pancreato Biliary Association·2026
Same author

Genetically driven immune microenvironment states associate with therapeutic responses in MYD88 mutant lymphomas.

Molecular cancer·2026
Same author

Neoadjuvant Therapy for Localized Pancreatic Cancer.

Cancers·2026
Same author

Quantification of DNA Methylation for Diagnosis and Monitoring of Hepatocellular Carcinoma.

Journal of the American College of Surgeons·2026

Related Experiment Video

Updated: Apr 24, 2026

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

941

Pyk2 promotes tumor progression in multiple myeloma.

Yu Zhang1, Michele Moschetta2, Daisy Huynh2

  • 1Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; The First People's Hospital of Yunnan Province, Department of Gastroenterology, Kunming, China;

Blood
|September 14, 2014
PubMed
Summary

Proline-rich tyrosine kinase 2 (Pyk2) drives multiple myeloma (MM) progression by promoting tumor growth and cell proliferation. Inhibiting Pyk2 with VS-4718 offers a potential new therapeutic strategy for MM patients.

More Related Videos

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
10:04

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Published on: May 1, 2015

12.5K
Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

6.1K

Related Experiment Videos

Last Updated: Apr 24, 2026

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

941
Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
10:04

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Published on: May 1, 2015

12.5K
Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

6.1K

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Proline-rich tyrosine kinase 2 (Pyk2), a focal adhesion kinase family member, is implicated in tumor development.
  • The specific role of Pyk2 in multiple myeloma (MM) pathogenesis is not well understood.

Purpose of the Study:

  • To investigate the role of Pyk2 in multiple myeloma (MM) biology and disease progression.
  • To evaluate Pyk2 as a potential therapeutic target in MM.

Main Methods:

  • Assessed Pyk2 expression in MM patients versus healthy individuals.
  • Utilized loss-of-function approaches (Pyk2 inhibition) and overexpression studies in MM cells.
  • Investigated the impact of Pyk2 on Wnt/β-catenin signaling pathway components (β-catenin, c-Myc, Cyclin D1).
  • Tested the efficacy of the FAK/Pyk2 inhibitor VS-4718 in vitro and in vivo.

Main Results:

  • Pyk2 expression is significantly higher in patients with MM compared to healthy individuals.
  • Pyk2 inhibition reduced MM tumor growth, cell proliferation, cell-cycle progression, and adhesion.
  • Pyk2 overexpression enhanced tumor growth and reduced survival in MM models.
  • Pyk2 inhibition destabilized β-catenin, downregulating c-Myc and Cyclin D1, thereby inhibiting Wnt/β-catenin signaling.
  • VS-4718 treatment effectively inhibited MM cell growth both in vitro and in vivo.

Conclusions:

  • Pyk2 plays a crucial tumor-promoting role in multiple myeloma.
  • Targeting Pyk2, potentially with inhibitors like VS-4718, represents a promising therapeutic avenue for MM.